MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-48846-2
Abstract: Osteosarcoma is the most prevalent primary bone malignancy in children and young adults. Resistance to chemotherapy remains a key challenge for effective treatment of patients with osteosarcoma. The aim of the present study was to… read more here.
Keywords: chemotherapy; response; predictive biomarker; osteosarcoma ... See more keywords